Montalban-Bravo G, Jabbour E, Borthakur G, Kadia T, et al. Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents. Br J Haematol 2024;204:898-909.
PMID: 37946611